Armistice Capital’s Onconetix ONCO Stock Holding History

Armistice Capital’s Portfolio ONCO Stock Details ONCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7	Closed	-$577K	–	345
2023 Q3	$577K	Buy	+7	New	+$1.07M	0.01%	161
2022 Q4	–	Sell	-5	Closed	-$1.47M	–	225
2022 Q3	$1.47M	Buy	+5	New	+$2.19M	0.03%	132

Other funds holding ONCO

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's ONCO Position: Q4 2023 in Review

Armistice Capital sold out of Onconetix (ONCO) in Q4 2023, closing a stake of 7 shares — an estimated $577K sold.

Armistice Capital first reported a position in ONCO in Q3 2022 and held it in 2 quarters. The position peaked at $1.47M in Q3 2022. 4 funds tracked by Wall St. Rank hold ONCO as of Q4 2023.

Armistice Capital reported no remaining Onconetix position as of Q4 2023 after selling out during the quarter.
Armistice Capital sold 7 Onconetix shares in Q4 2023, an estimated $577K.
Armistice Capital first reported a position in Onconetix in Q3 2022 and held it in 2 quarters.
Armistice Capital's Onconetix position peaked at $1.47M in Q3 2022.
4 funds tracked by Wall St. Rank held Onconetix as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.